Page last updated: 2024-08-26

sr141716 and Psychotic Disorders

sr141716 has been researched along with Psychotic Disorders in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheer, JF; Glick, SD; Morra, JT1
Arvanitis, L; Bauer, D; Meltzer, HY; Rein, W1

Trials

1 trial(s) available for sr141716 and Psychotic Disorders

ArticleYear
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
    The American journal of psychiatry, 2004, Volume: 161, Issue:6

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cannabinoids; Double-Blind Method; Drugs, Investigational; Female; Haloperidol; Humans; Male; Middle Aged; Neurotensin; Peptide Fragments; Piperidines; Placebos; Psychotic Disorders; Pyrazoles; Pyrrolidonecarboxylic Acid; Receptors, Neurokinin-3; Research Design; Rimonabant; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome

2004

Other Studies

1 other study(ies) available for sr141716 and Psychotic Disorders

ArticleYear
Cannabinoid receptors mediate methamphetamine induction of high frequency gamma oscillations in the nucleus accumbens.
    Neuropharmacology, 2012, Volume: 63, Issue:4

    Topics: Animals; Brain Waves; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Central Nervous System Stimulants; Disease Models, Animal; Dose-Response Relationship, Drug; Interneurons; Male; Methamphetamine; Nerve Tissue Proteins; Neurotoxicity Syndromes; Nucleus Accumbens; Piperidines; Psychomotor Performance; Psychotic Disorders; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptors, Cannabinoid; Rimonabant

2012